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TO THE EDITOR
Oculocutaneous albinism (OCA) is an
autosomal recessive disorder character-
ized by hypomelanosis of the skin, hair,
and eyes, associated with reduced
visual acuity, nystagmus, and photopho-
bia (Tomita and Suzuki, 2004). Its
worldwide prevalence is approximately
1:17,000 (Witkop, 1979). Hypopigmen-
tation or complete lack of pigmentation
is caused by a deficiency involving the
production, metabolism, or distribution
of melanin, the main pigment respon-
sible for skin coloration. Diagnosis is
based on clinical findings of hypopig-
mentation of the skin and hair, in
addition to the characteristic ocular
symptoms. OCA can be isolated or asso-
ciated with other anomalies in syndro-
mic forms (Tomita and Suzuki, 2004).
Mutations of the TYR, OCA2, TYRP1,
and SLC45A2 genes have been
associated with non-syndromic forms
of OCA (OCA1–4, respectively). As
these four genes do not account for all
non-syndromic OCA, it has long been
hypothesized that other genes might be
involved. To date, more than 125 genes
have been involved in pigmentation
regulation, and many of them (at least
25) affect the biogenesis or function of
melanosomes. Several genes encoding
melanosomal proteins including TYRP2,
SLC24A5, SILV, RAB7, and RAB38 have
been considered as good candidates
for OCA. However, until recently, no
pathological mutations of these genes
had been reported in human OCA pati-
ents (Suzuki et al., 2003, Hutton and
Spritz, 2008, Grnskov et al., 2009,
Mondal et al., 2012). Very recently,
two new OCA genes were uncovered.
Mutations of C10orf11 were identified
in a family from the Faroe Islands and in
a Lithuanian patient (Grnskov et al.,
2013), and mutations of SLC24A5 were
found in a Chinese patient presenting
with non-syndromic OCA (Wei et al.,
2013). In addition, an OCA locus was
mapped to 4q24 in a consanguineous
Pakistani family, but the gene has not
yet been described (Kausar et al., 2012).
We analyzed 399 patients with non-
syndromic OCA and found that 36%
were OCA1, 25% had mutations in
OCA2, 2% were OCA3, and 11%
were caused by mutations in SLC45A2
(OCA4). An additional 6% of patients
had mutations in GPR143 (OA1) and
1% in HPS1. Six percent of patients had
a single heterozygous mutation in one
gene, and in 13% no mutation in the
known genes was identified (our unpub-
lished data). Subsequently, we sequen-
ced the nine exons of the SLC24A5 gene
in 22 OCA patients without mutations
in any of the known genes (OCA1–4,
OA1, and HPS1 genes) and foundAccepted article preview online 28 August 2013; published online 3 October 2013
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5 index patients with biallelic mutations
(Table 1). No intragenic rearrangement
(deletions, duplications) was identified.
Patients 060854, 070126, and 110299
were homozygous for mutations
c.590þ4A4G, c.641delT/p.Leu214
ArgfsX12, and c.546T4A/p.Ser182Arg,
respectively. The affected brother
(131242) and first cousin (0710127) of
patient 070126 were also homozygous
for the c.641delT/p.Leu214ArgfsX12
mutation. His unaffected brother was
heterozygous for the mutation.
Compound heterozygosity was found
in patients 100404 (c.344C4A/
p.Ala115Glu and c.989G4A/p.Trp330X)
and 120233 (c.216T4A/p.Tyr72X and a
c.344C4A/p.Ala115Glu). All the identi-
fied mutations were inherited from het-
erozygous parents and were absent from
single-nucleotide polymorphism data-
bases (HapMap, 1000 Genomes). The
two missense mutations c.546T4A/
p.Ser182Arg and c.344C4A/p.Ala115-
Glu were predicted to be probably
damaging by the prediction software
Polyphen2. Moreover they affected
highly conserved amino acids.
We observed a heterogeneous pheno-
type among the seven OCA patients with
SLC24A5 mutations reported herein
(Table 1 and Figure 1). Severe hypopig-
mentation similar to that observed in
OCA1 (white platinum golden hair and
complete iris transillumination) was
observed in patient 100404, whereas a
milder skin phenotype with light brown
hair was observed in four patients.
Patient 110299 had light brown hair,
but no skin pigmentation, revealing sub-
cutaneous vascular structures. No ocular
pigmentation was observed, with com-
plete iris transillumination and absent
pigmentation of the retinal pigment
epithelium and choroid on fundoscopy.
However, patient 120233, who had
darker hair, displayed some degree of
ocular pigmentation. The patient pub-
lished by Wei et al. (2013) also had
blond/light brown hair. Obviously, solid
genotype–phenotype correlations cannot
yet be established because of the small
number of OCA6 patients identified to
date. Ophthalmologic anomalies were
always present and included reduced
best-corrected visual acuity, nystagmus,
pronounced iris transillumination, severe
retinal hypopigmentation, and foveal
hypoplasia. No other findings evocative
of syndromic OCA, including bleeding,
granulomatous colitis, pulmonary invol-
vement, or propensity to infections, were
recorded.
SLC24A5 encodes a trans-Golgi net-
work protein with potassium-dependent
sodium–calcium exchange activity that
regulates human epidermal melanogen-
esis (Ginger et al., 2008). Slc24a5-null
mice have been reported to have
albinotic features (Vogel et al., 2008).
Slc24a5 mutations are responsible for
the golden mutant in the zebrafish, in
which melanosomal changes have been
identified. Slc24a5 was considered to be
a putative cation exchanger (nckx5) that
localizes to an intracellular membrane,
likely the melanosome or its precursor,
in golden. The human ortholog of
slc24a5 is highly conserved (68% at
the mRNA level; 69% at the protein
level) and was shown to be functional in
the zebrafish (Lamason et al., 2005).
A genome-wide association study
performed in a South Asian population
showed that SLC24A5 single-nucleotide
polymorphism rs1426654 (Ala111Thr)
was associated with lighter skin in
Thr111-positive individuals, and might
be a natural regulator of human skin
color variation (Stokowski et al., 2007).
Wei et al. (2013) reported less mature
and more immature melanosomes in
epidermal melanocytes of their OCA6
patient, supporting the involvement
of SLC24A5 in the maturation of
melanosomes or in the production of
pigment in mature melanosomes. It was
shown that HPS protein–associated
complexes such as AP-3, BLOC-1, and
BLOC-2 mediated the transport of mel-
anosomal proteins such as Tyrosinase,
TYRP1, OCA2, and ATP7A into mature
melanosomes (Wei and Li, 2013). It was
also suggested that BLOC-1 and BLOC-
2, involved in Hermanski–Pudlak syn-
drome, could mediate the melanosomal
targeting of SLC24A5, but this requires
further investigations.
Our finding of mutations in SLC24A5
in five unrelated families strengthens the
importance of screening this gene in
OCA, and indicates that OCA6 is not
restricted to the Chinese population and
accounts for 1.25% of OCA patients in
Patient 100404
Patient 110299
Patient 120233
Figure 1. Phenotype of patients 100404, 110299, and 120233. Hair color is shown on the left, illustrating
the phenotypic heterogeneity in patients with OCA6. Ocular phenotype is objectivized by iris
transillumination (patient 100404) or eye fundus (patients 110299 and 120233) on the right.
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our series. Still, 11.5% of patients have
no mutation after extensive analysis of
the OCA1–4, OCA6, OA1, and HPS1
genes, thus suggesting that other genes
involved in OCA still remain to be
identified.
Written informed consent was
received from the patients. The authors
adhere to the Declaration of Helsinki
Principles. Experiments were approved
by the Comite´ de protection des Per-
sonnes Bordeaux—Outre Mer III.
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TO THE EDITOR
Revertant mosaicism is the coexistence
of mutant cells carrying germline
mutations and revertant cells that have
spontaneously corrected the germline
mutation by a somatic reverse mutation.
Revertant mosaicism has been reported
for a number of genetic diseases
(Pasmooij and Jonkman, 2012), includ-
ing epidermolysis bullosa. Moreover,
the first case of revertant mosaicism in
skin was found in a Dutch patient
026-01 with junctional epidermolysis
bullosa caused by mutations in
COL17A1. The patient was compound
heterozygous for a maternal deletion in
exon 18, c.1601delA, and paternal
nonsense mutation in exon 51,
c.3676C4T (Jonkman et al, 1997).
Owing to gene conversion, the
c.1601delA mutation was corrected
and the patient presented a clinically
healthy skin patch on her forearm
(Figure 1a), where affected (mutant)
and corrected (revertant) keratinocytes
coexisted (Figure 1b). Recently, we
found revertant mosaicism to occur in
all Dutch patients with junctional epi-
dermolysis bullosa (Jonkman and
Pasmooij, 2009; Pasmooij et al, 2012).
Naturally corrected keratinocytes
expressing type XVII collagen (C17)
harvested from a revertant patch can
be used for autologous cell therapy.Accepted article preview online 24 July 2013; published online 15 August 2013
Abbreviation: C17, type XVII collagen
A Gostyn´ski et al.
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